KORU Medical Systems (NASDAQ:KRMD) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of KORU Medical Systems (NASDAQ:KRMD – Free Report) from a hold rating to a buy rating in a report issued on Sunday morning,Wall Street Zen reports.

Several other research firms also recently weighed in on KRMD. Craig Hallum reiterated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research note on Thursday, August 6th. Piper Sandler restated a “neutral” rating and issued a $4.50 price objective (down from $5.00) on shares of KORU Medical Systems in a research note on Wednesday, November 11th. Weiss Ratings downgraded KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 29th. Finally, Zacks Research downgraded KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Friday, October 30th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.50.

Read Our Latest Research Report on KORU Medical Systems

KORU Medical Systems Price Performance

KRMD opened at $3.70 on Friday. KORU Medical Systems has a 52-week low of $2.86 and a 52-week high of $6.61. The company has a market cap of $160.51 million, a P/E ratio of -185.00 and a beta of 0.47. The firm’s 50-day moving average price is $3.15 and its 200-day moving average price is $3.92.

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04. KORU Medical Systems had a negative net margin of 1.78% and a negative return on equity of 4.62%. The company had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.33 million. On average, research analysts anticipate that KORU Medical Systems will post -0.02 EPS for the current fiscal year.

Insider Transactions at KORU Medical Systems

In related news, insider Adam Kalbermatten purchased 32,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was bought at an average cost of $3.16 per share, with a total value of $101,120.00. Following the completion of the acquisition, the insider owned 394,017 shares of the company’s stock, valued at $1,245,093.72. The trade was a 8.84% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 18.50% of the company’s stock.

Institutional Trading of KORU Medical Systems

A number of hedge funds have recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new position in KORU Medical Systems in the third quarter valued at $41,000. Bard Associates Inc. purchased a new stake in shares of KORU Medical Systems during the 2nd quarter worth about $61,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of KORU Medical Systems during the 1st quarter worth about $79,000. Algert Global LLC boosted its stake in shares of KORU Medical Systems by 57.2% during the 2nd quarter. Algert Global LLC now owns 22,737 shares of the company’s stock worth $95,000 after acquiring an additional 8,270 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of KORU Medical Systems during the 2nd quarter valued at about $124,000. 58.60% of the stock is owned by hedge funds and other institutional investors.

KORU Medical Systems Company Profile

(Get Free Report)

KORU Medical Systems develops, manufactures and markets medical devices used to deliver medications under the skin, or subcutaneously. Its products are designed for patients receiving therapies outside traditional infusion settings, including at home. The company’s product line includes the Freedom60 and FreedomEDGE ambulatory infusion pumps, Precision Flow Rate Tubing and HIgH-Flo subcutaneous needle sets. These products are used with subcutaneous immunoglobulin and other specialty therapies. Founded in 1980 as Repro Med Systems, the company adopted the name KORU Medical Systems in 2020.

Further Reading

Analyst Recommendations for KORU Medical Systems (NASDAQ:KRMD)

Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.